REFERENCES
1. Francisco G, Hernandez C, Simo R. Serum markers of vascular inflammation in dyslipemia. Clin Chim Acta 2006; 369: 1-16.
2. Mamo JC, Proctor SD, Smith D. Retention of chylomicron remnants by arterial tissue; importance of an efficient clearance mechanism from plasma. Atherosclerosis 1998; 141 Suppl 1: S63-9.
3. Vogel RA, Corretti MC, Plotnick GD. Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol 1997; 79: 350-4.
4. Shojaee-Moradie F, Ma Y, Lou S, Hovorka R, Umpleby AM. Prandial hypertriglyceridemia in metabolic syndrome is due to an overproduction of both chylomicron and VLDL triacylglycerol. Diabetes 2013; 62: 4063-9.
5. Gill JM, Mees GP, Frayn KN, Hardman AE. Moderate exercise, postprandial lipaemia and triacylglycerol clearance. Eur J Clin Invest 2001; 31: 201-7.
6. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
7. Mora-Rodriguez R, Ortega JF, Morales-Palomo F, Ramirez-Jimenez M, Moreno-Cabanas A. Effects of statins therapy and exercise on postprandial triglycerides in overweight individuals with hypercholesterolemia. Br J Clin Pharmacol 2020.
8. Parhofer KG, Laubach E, Barrett PH. Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients. J Lipid Res 2003; 44: 1192-8.
9. Schoonjans K, Peinado-Onsurbe J, Fruchart JC, Tailleux A, Fievet C, Auwerx J. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Lett 1999; 452: 160-4.
10. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC, Jr., International Diabetes Federation Task Force on E, Prevention, Hational Heart L, Blood I, American Heart A, World Heart F, International Atherosclerosis S, International Association for the Study of O. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
11. Moreno-Cabanas A, Ortega JF, Morales-Palomo F, Ramirez-Jimenez M, Mora-Rodriguez R. Importance of a verification test to accurately assess VO2 max in unfit individuals with obesity. Scand J Med Sci Sports 2020; 30: 583-90.
12. Freese EC, Gist NH, Cureton KJ. Effect of prior exercise on postprandial lipemia: an updated quantitative review. J Appl Physiol (1985) 2014; 116: 67-75.
13. Maraki MI, Sidossis LS. The latest on the effect of prior exercise on postprandial lipaemia. Sports Med 2013; 43: 463-81.
14. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990; 300: 230-5.
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
16. Mestek ML, Plaisance EP, Ratcliff LA, Taylor JK, Wee SO, Grandjean PW. Aerobic exercise and postprandial lipemia in men with the metabolic syndrome. Med Sci Sports Exerc 2008; 40: 2105-11.
17. Zhang JQ, Ji LL, Fretwell VS, Nunez G. Effect of exercise on postprandial lipemia in men with hypertriglyceridemia. Eur J Appl Physiol 2006; 98: 575-82.
18. MacEneaney OJ, Harrison M, O’Gorman DJ, Pankratieva EV, O’Connor PL, Moyna NM. Effect of prior exercise on postprandial lipemia and markers of inflammation and endothelial activation in normal weight and overweight adolescent boys. Eur J Appl Physiol 2009; 106: 721-9.
19. Gill JM, Al-Mamari A, Ferrell WR, Cleland SJ, Packard CJ, Sattar N, Petrie JR, Caslake MJ. Effects of prior moderate exercise on postprandial metabolism and vascular function in lean and centrally obese men. Journal of the American College of Cardiology 2004; 44: 2375-82.
20. Cox-York KA, Sharp TA, Stotz SA, Bessesen DH, Pagliassotti MJ, Horton TJ. The effects of sex, metabolic syndrome and exercise on postprandial lipemia. Metabolism 2013; 62: 244-54.
21. Dalgaard M, Thomsen C, Hermansen K. Effects of one single bout of low-intensity exercise on postprandial lipaemia in type 2 diabetic men. Br J Nutr 2004; 92: 469-76.
22. Gill JM, Al-Mamari A, Ferrell WR, Cleland SJ, Perry CG, Sattar N, Packard CJ, Caslake MJ, Petrie JR. Effect of prior moderate exercise on postprandial metabolism in men with type 2 diabetes: heterogeneity of responses. Atherosclerosis 2007; 194: 134-43.
23. Parhofer KG, Barrett PH, Schwandt P. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects. J Clin Endocrinol Metab 2000; 85: 4224-30.
24. Dane-Stewart CA, Watts GF, Pal S, Chan D, Thompson P, Hung J, Mamo JC. Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease. Metabolism 2003; 52: 1279-86.
25. Chan DC, Watts GF, Somaratne R, Wasserman SM, Scott R, Barrett PHR. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism. Arterioscler Thromb Vasc Biol 2018; 38: 1644-55.
26. Lamon-Fava S, Diffenderfer MR, Barrett PH, Buchsbaum A, Matthan NR, Lichtenstein AH, Dolnikowski GG, Horvath K, Asztalos BF, Zago V, Schaefer EJ. Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism. J Lipid Res 2007; 48: 1746-53.
27. Schneider JG, von Eynatten M, Parhofer KG, Volkmer JE, Schiekofer S, Hamann A, Nawroth PP, Dugi KA. Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo. Atherosclerosis 2004; 175: 325-31.
28. Battula SB, Fitzsimons O, Moreno S, Owens D, Collins P, Johnson A, Tomkin GH. Postprandial apolipoprotein B48-and B100-containing lipoproteins in type 2 diabetes: do statins have a specific effect on triglyceride metabolism? Metabolism 2000; 49: 1049-54.
29. Williams ML, Menon GK, Hanley KP. HMG-CoA reductase inhibitors perturb fatty acid metabolism and induce peroxisomes in keratinocytes. J Lipid Res 1992; 33: 193-208.